Core Insights - Pfizer Inc. reported a decline in fourth-quarter revenue primarily due to reduced demand for COVID-19 products, although earnings exceeded analyst forecasts due to strong performance in vaccines and oncology [1][3] Revenue Performance - Operational revenue for the quarter ended December 31 decreased by 3% to $17.6 billion, surpassing Bloomberg consensus estimates of $16.94 billion [3] - Revenue from Pfizer's COVID-19 vaccine fell by 35% year over year, while sales of its antiviral COVID treatment dropped by 70%, attributed to lower infection rates and reduced utilization in the U.S. [1] Product Performance - Strong growth was observed in Abrysvo, Pfizer's respiratory syncytial virus vaccine for adults aged 18 to 59 at risk, with global sales increasing by 136% due to international demand and pricing [2] - Oncology biosimilars also showed significant growth, with sales rising by 76% year over year [2] Earnings and Guidance - Adjusted earnings per share for the quarter were reported at $0.66, exceeding expectations of $0.57 [3] - Pfizer reaffirmed its full-year guidance, projecting revenue between $59.5 billion and $62.5 billion and adjusted diluted EPS of $2.80 to $3.00 [3] Clinical Developments - Pfizer's experimental obesity treatment showed promising results, demonstrating up to 12.3% weight loss in non-diabetic patients during a mid-stage clinical trial [4]

Core Insights - Pfizer demonstrated robust operational resilience during its strategic transformation phase, with total revenue reaching $62.6 billion in 2025, reflecting a 6% growth in core business excluding COVID-related products [1][4] - The company maintained its 2026 performance guidance while revealing an active product pipeline, expecting to initiate approximately 20 key clinical trials in 2026, laying the foundation for long-term growth [1][4] Financial Performance - Total revenue for Q4 2025 was $17.6 billion, a 1% decrease from Q4 2024, while full-year revenue decreased by 2% to $62.6 billion [2] - Adjusted diluted EPS for Q4 was $0.66, a 5% increase year-over-year, and for the full year, it reached $3.22, up 4% [2][3] - The adjusted sales cost ratio improved to 24.2%, down from 25.8% in 2024, indicating enhanced cost management [8] Business Segments - Non-COVID product lines showed strong structural growth, with cardiovascular and vaccine segments leading the way; Eliquis generated $8 billion in revenue, a growth of 8% [4][5] - The oncology business achieved $16.8 billion in revenue, an 8% increase, with key products like Ibrance and Xtandi maintaining strong market positions despite competition [6] - COVID-related product revenues significantly declined, with Comirnaty and Paxlovid generating $4.4 billion and $2.4 billion respectively, down 18% and 59% year-over-year [7] Strategic Initiatives - Pfizer completed the acquisition of Metsera for approximately $7 billion, marking its entry into the obesity and metabolic disease treatment market [9] - The company is advancing its obesity pipeline, with promising results from the clinical trials of its long-acting GLP-1 receptor agonist [10] - Multiple oncology products received regulatory breakthroughs, enhancing the competitive edge of Pfizer's oncology portfolio [11][12] 2026 Outlook - Pfizer projects 2026 revenue between $59.5 billion and $62.5 billion, including approximately $5 billion from COVID-related products [13] - The company plans to maintain a focus on reducing debt levels and balancing its capital structure, with no share buybacks planned for 2026 [13]

On Tuesday morning , Pfizer Inc. ( PFE ) released Q4 and full-year 2025 earnings. The report was solid overall but missed estimates in some respects, causing shares to decline ~5% in the pre-market. The knee-jerk selling was causedBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-F ...

On Tuesday morning , Pfizer Inc. ( PFE ) released Q4 and full-year 2025 earnings. The report was solid overall but missed estimates in some respects, causing shares to decline ~5% in the pre-market. The knee-jerk selling was causedBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-F ...

Core Insights - Pfizer has met its fiscal year 2025 financial targets, generating revenues of $62.6 billion, which aligns with its adjusted profit forecast but reflects a 2% operational decline from FY24 [2][3] Financial Performance - Full-year revenues for FY25 were $62.6 billion, meeting the adjusted profit forecast of $62 billion, but showing a 2% operational decline compared to FY24 [2] - Earnings per share (EPS) for FY25 were $1.36, consistent with analyst consensus but lower than the FY24 EPS of $1.41 [2] - Pfizer reaffirmed its 2026 financial guidance, expecting revenues between $59.5 billion and $62.5 billion, with a diluted EPS range of $2.80 to $3.00 [2] Challenges and Revenue Losses - Pfizer faced challenges in FY25 due to declining Covid-19 vaccine sales and impending patent expirations, forecasting $1.5 billion in revenue losses for FY26 [3] - Excluding Covid-19 vaccine sales, the rest of Pfizer's pipeline achieved a 6% operational growth [4] Key Product Performance - The RSV vaccine, Abrysvo, generated $1 billion in sales, a 37% increase from FY24, helping to offset a 9% revenue decline in the US [5] - Eliquis, a blood thinner, saw an 8% sales increase to $7.96 billion, although its growth may be limited due to upcoming patent expirations [6] - In oncology, Padcev generated $1.94 billion in sales, a 22% increase from FY24, while Lorbrena achieved blockbuster status with a 40% year-over-year growth [7] Market Reaction - Following the FY25 results, Pfizer's stock value dropped by 4.9%, from $26.66 to $25.36, indicating investor dissatisfaction despite meeting revenue targets [8]

Core Insights - Pfizer reported fourth-quarter 2025 adjusted earnings per share of 66 cents, exceeding the Zacks Consensus Estimate of 57 cents, with a year-over-year earnings increase of 5% [1] - Total revenues for the quarter were $17.6 billion, a decline of 1% year-over-year on a reported basis and 3% on an operational basis, primarily due to decreased revenues from COVID-19 products [2] Revenue Breakdown - International revenues decreased by 4% on an operational basis to $8.44 billion, while U.S. revenues fell by 1% to $9.1 billion [2] - The Primary Care segment saw a 13% operational decline in sales to $7.94 billion, while Specialty Care recorded a 6% increase to $4.77 billion, and Oncology sales rose by 8% to $4.44 billion [3] Product Performance - Eliquis sales in Primary Care rose by 8% to $2.02 billion, although alliance revenues fell short of the Zacks Consensus Estimate of $2.14 billion [4] - Global revenues from the Prevnar family increased by 8% to $1.71 billion, surpassing the Zacks Consensus Estimate of $1.65 billion [5] - Comirnaty sales were $2.27 billion, down 35% year-over-year, but still beat the Zacks Consensus Estimate of $2.0 billion [6] - Paxlovid revenues dropped by 70% year-over-year to $218 million, missing the Zacks Consensus Estimate of $289 million [7] Full-Year Results - For the full year 2025, Pfizer's sales declined by 2% to $62.6 billion, exceeding the Zacks Consensus Estimate of $61.94 billion [14] - Adjusted earnings for 2025 were $3.22 per share, a 4% increase year-over-year, beating the Zacks Consensus Estimate of $3.13 [14] 2026 Guidance - Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, reflecting a decline from 2025 due to lower COVID product revenues and an impending patent cliff [16] - COVID sales are projected to be around $5 billion in 2026, down from approximately $6.7 billion in 2025 [17] - Adjusted earnings per share for 2026 are expected to be in the range of $2.80-$3.00, a decrease from 2025's EPS of $3.22 [17] Research and Development - Pfizer plans to initiate 20 pivotal studies in 2026, including 10 for ultra-long-acting obesity candidates from the Metsera acquisition [26] - Positive top-line data from a phase IIb study on PF-08653944 showed significant weight reduction, positioning Pfizer competitively against other weight loss therapies [20][21]

Pfizer Stock Dives On Modest Guidance, Obesity Update; Can It Catch Eli Lilly? | Investor's Business DailyBREAKING: [Stocks Edge Higher As Teradyne, Palantir Surge]---Pfizer (PFE) stock toppled Tuesday after the S&P health giant reaffirmed its modest outlook for 2026 despite easily beating Wall Street's fourth- quarter expectations. The company also provided an update on its obesity treatment, MET-097i, saying patients who tested a weekly dose for 12 weeks followed by monthly doses up to 28 weeks lost, on a ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.The Dow traded down 0.19% to 49,316.23 while the NASDAQ dipped 1.23% to 23,302.18. The S&P 500 also fell, dropping, 0.62% to 6,933.29.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsMaterials shares gained by 1.8% on Tuesday.In trading on Tuesday, information technology stocks fell by 1.9%.Top HeadlineOn Tuesday, Pfizer Inc. (NYSE:PFE) sh ...

Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:PFE).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted 21 un ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.The Dow traded down 0.19% to 49,316.23 while the NASDAQ dipped 1.23% to 23,302.18. The S&P 500 also fell, dropping, 0.62% to 6,933.29.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsMaterials shares gained by 1.8% on Tuesday.In trading on Tuesday, information technology stocks fell by 1.9%.Top HeadlineOn Tuesday, Pfizer Inc. (NYSE:PFE) sh ...